CRIS Current Research Information System

SANTUCCI, MARIA ALESSANDRA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.509
AS - Asia 2.882
EU - Europa 2.319
AF - Africa 171
SA - Sud America 120
OC - Oceania 7
Continente sconosciuto - Info sul continente non disponibili 1
Totale 9.009
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.461
VN - Vietnam 846
SG - Singapore 798
CN - Cina 712
GB - Regno Unito 613
DE - Germania 320
SE - Svezia 290
IT - Italia 234
UA - Ucraina 194
HK - Hong Kong 144
FR - Francia 142
RU - Federazione Russa 134
IN - India 120
IE - Irlanda 92
NL - Olanda 86
BR - Brasile 83
JP - Giappone 58
TG - Togo 54
ZA - Sudafrica 54
EE - Estonia 42
FI - Finlandia 37
KR - Corea 33
CH - Svizzera 31
JO - Giordania 27
CA - Canada 24
TH - Thailandia 22
BD - Bangladesh 20
BG - Bulgaria 20
SC - Seychelles 19
BE - Belgio 17
CI - Costa d'Avorio 16
MX - Messico 16
NG - Nigeria 15
AR - Argentina 13
IR - Iran 13
GR - Grecia 12
ID - Indonesia 12
IQ - Iraq 11
PH - Filippine 10
PL - Polonia 10
RO - Romania 9
CZ - Repubblica Ceca 8
SA - Arabia Saudita 8
TW - Taiwan 8
EC - Ecuador 7
LT - Lituania 7
TR - Turchia 7
UZ - Uzbekistan 7
AU - Australia 6
HR - Croazia 6
PK - Pakistan 6
ES - Italia 5
NP - Nepal 5
CL - Cile 4
PE - Perù 4
VE - Venezuela 4
AE - Emirati Arabi Uniti 3
AT - Austria 3
DZ - Algeria 3
MA - Marocco 3
CO - Colombia 2
EG - Egitto 2
GE - Georgia 2
IL - Israele 2
JM - Giamaica 2
KH - Cambogia 2
LB - Libano 2
MD - Moldavia 2
PT - Portogallo 2
PY - Paraguay 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AM - Armenia 1
BO - Bolivia 1
CR - Costa Rica 1
CU - Cuba 1
ET - Etiopia 1
GI - Gibilterra 1
GM - Gambi 1
GT - Guatemala 1
HU - Ungheria 1
KN - Saint Kitts e Nevis 1
KW - Kuwait 1
MU - Mauritius 1
MY - Malesia 1
NI - Nicaragua 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
PS - Palestinian Territory 1
VI - Stati Uniti Isole Vergini 1
ZM - Zambia 1
ZW - Zimbabwe 1
Totale 9.009
Salva come PNG Salva come JPEG
Città #
Singapore 564
Southend 514
Ashburn 373
Chandler 317
Fairfield 315
San Jose 210
Wilmington 173
Seattle 164
Dong Ket 160
Woodbridge 152
Houston 141
Ho Chi Minh City 140
Jacksonville 137
Hong Kong 133
Hanoi 127
Ann Arbor 126
Princeton 111
Beijing 110
Cambridge 107
Dublin 91
Hefei 88
Boardman 71
Santa Clara 70
Nanjing 60
Lomé 54
Westminster 53
Padova 52
Los Angeles 47
New York 47
Tokyo 47
Lauterbourg 44
Berlin 41
Helsinki 36
Council Bluffs 34
Bologna 32
Frankfurt am Main 32
Bern 28
Jinan 28
Buffalo 27
Amman 26
Seoul 26
Shenyang 24
Da Nang 23
Milan 21
Changsha 20
Medford 20
Mülheim 20
San Diego 20
Sofia 20
Falkenstein 19
Falls Church 19
Hebei 19
Saint Petersburg 18
Abidjan 16
Brussels 16
Abeokuta 15
Haiphong 15
Nanchang 15
Redmond 15
Tianjin 15
Verona 15
Phoenix 14
Guangzhou 13
Taizhou 13
Shanghai 12
Des Moines 11
Hangzhou 11
London 11
Bengaluru 10
Redondo Beach 10
Turin 10
Bangkok 9
Mahé 9
São Paulo 9
Toronto 9
Zhengzhou 9
Dallas 8
Dearborn 8
Jakarta 8
Kuban 8
Norwalk 8
Washington 8
Xi'an 8
Bühl 7
Jiaxing 7
Johannesburg 7
Montreal 7
Munich 7
Ningbo 7
Rome 7
Baghdad 6
Bremen 6
Brooklyn 6
Florence 6
Harbin 6
Long Xuyen 6
Nuremberg 6
Portsmouth 6
The Dalles 6
Andover 5
Totale 5.797
Salva come PNG Salva come JPEG
Nome #
A calpain-cleaved fragment of β-catenin promotes BCRABL1+ cell survival evoked by autophagy induction in response to imatinib 275
14-3-3 Binding and Sumoylation Concur to the Down-Modulation of β-catenin Antagonist chibby 1 in Chronic Myeloid Leukemia 267
9-Hydroxystearic acid upregulates p21WAF1 in HT29 cancer cells. 264
BCR-ABL1-associated reduction of beta catenin antagonist Chibby1 in chronic myeloid leukemia. 244
NEW STRATEGIES IN THE TREATMENT OF CHRONIC MYELOID LEUKEMIA. COMBINED USE OF SRC AND TYROSINE KINASE INHIBITORS CIRCUMVENTS THE DEVELOPMENT OF DRUG-RESISTANCE 231
Hyper-activation of Aurora kinase a-polo-like kinase 1-FOXM1 axis promotes chronic myeloid leukemia resistance to tyrosine kinase inhibitors 228
Chibby drives β catenin cytoplasmic accumulation leading to activation of the unfolded protein response in BCR-ABL1+ cells 220
Chibby 1: A new component of β-catenin-signaling in chronic myeloid leukemia 220
Acetylation of FOXO3a transcription factor in response to imatinib of chronic myeloid leukemia 201
CHK2 drives late G1/early S phase arrest of clonal myeloid progenitors expressing the p210 BCR-ABL tyrosine kinase in response to STI571 201
14-3-3 ligand prevents nuclear import of c-ABL protein in chronic myeloid leukemia 198
9-HSA INDUCES APOPTOSIS AND INCREASES SENSITIVITY TO IMATINIB IN IMATINIB RESISTANT COLON CANCER CELLS 192
Apoptotic death of Bcr-Abl-expressing myeloid progenitors in response to the m-Tor inhibitor RAD001 (Everolimus) is promoted by the nuclear import of c-Abl 191
P210 Bcr-abl tyrosine kinase interaction with histone deacetylase 1 modifies histone H4 acetylation and chromatin structure of chronic myeloid leukaemia haematopoietic progenitors 188
Cytoplasmatic compartmentalization by Bcr-Abl promotes TET2 loss-of-function in chronic myeloid leukemia 187
Endoplasmic reticulum stress initiates apoptotic death induced by STI571 inhibition of p210 bcr-abl tyrosine kinase. 186
9-HSA INDUCES APOPTOSIS AND INCREASES SENSITIVITY TO IMATINIB IN IMATINIB RESISTANT COLON CANCER CELLS 185
Gadd45a transcriptional induction elicited by the Aurora kinase inhibitor MK-0457 in Bcr-Abl-expressing cells is driven by Oct-1 transcription factor 185
P53 and beta catenin cross-talk in the medulloblastoma cell line radiosensitivity 180
C6-Unsubstituted Pyrazolo[3,4-d]pyrimidines Are Dual Src/Abl Inhibitors Effective against Imatinib Mesylate Resistant Chronic Myeloid Leukemia Cell Lines. 178
HDAC1 (histone deacetylase1) involvement in Chronic Myeloid Leukemia 177
HIF 1 Alpha: A Suitable Target for Multiple Myeloma 174
Histone H3 covalent modifications driving response of BCR-ABL1+ cells sensitive and resistant to imatinib to Aurora kinase inhibitor MK-0457 173
FOXM1 Transcription Factor: A New Component of Chronic Myeloid Leukemia Stem Cell Proliferation Advantage 173
Persistent Cdk2 inactivation drives growth arrest of BCR-ABL-expressing cells in response to dual inhibitor of SRC and ABL kinases SKI606 172
The p210BCR-ABL tyrosine kinase of chronic myeloid leukemia causes resistance to radio-induced apoptotic death by inhibiting the proapoptotic BAX gene 170
HIF-1a INHIBITION PROMOTES CELL CYCLE ARREST IN MULTIPLE MYELOMA 168
FOXM1 Transcription Factor Is a Component of Beta Catenin Signaling in Hematopoietic Progenitors of Chronic Myeloid Leukemia 165
Ponatinib treatment in chronic myeloid leukemia cell lines targets aurora kinase A/FOXM1 axis 162
GENOMIC UNBALANCES ASSOCIATED WITH THE RESISTANCE TO IONIZING RADIATIONS OF A HUMAN OSTEOSARCOMA CELL LINE (SAOS) DETECTED BY COMPARATIVE GENOMIC HYBRIDIZATION (CGH-BASED TECHNIQUE) 159
Zinc-finger transcription factor slug contributes to the survival advantage of chronic myeloid leukemia cells. 159
Discovery and SAR of 1,3,4-thiadiazole derivatives as potent Abl tyrosine kinase inhibitors and cytodifferentiating agents. 158
mTOR inhibitor RAD001 (Everloimus) enhances the effects of imatinib in chronic myeloid leukemia by raising the nuclear expression of c-Abl protein 157
IPO-trimethylation of histone H3-lysine9 associated with P210 BCR-ABL tyrosine kinase of chronic myeloid leukaemia 156
Modulation of apoptotic signalling by 9-hydroxystearic acid in osteosarcoma cells 156
DNA methyltransferase 1 drives transcriptional down-modulation of β catenin antagonist Chibby1 associated with the BCR-ABL1 gene of chronic myeloid leukemia. 150
Tyrosine kinase inhibotr STI571 (Imatinib) cooperates with wild type p53 on k562 cell line to enhance its pro-apoptotic effets 150
The m-TOR inhibitor everolimus complements pro-apoptotic and anti-proliferative effects of imatinib on chronic myeloid leukemia progenitors by promoting the nuclear import of normal c-Abl protein 149
Genomic instability in the development of non-Hodgkin lymphomas secondary to Hodgkin lymphoma 142
New SRC/ABL inhibitors for chronic myeloid leukemia therapy show selectivity for T315I ABL mutant CD34(+) cells 142
COVALENT MODIFICATIONS OF HISTONE H4 NH2-TERMINAL TAILS ASSOCIATED WITH P210 BCR-ABL TYROSINE KINASE 141
P210 BCR-ABL TYROSINE KINASE INHIBITS APOPTOTIC CELL DEATH THROUGH MULTIPLE PATHWAYS PREVENTING EARLY MITOCHONDRIAL ACTIVATION 139
Cyclin-dependent kinase 2 (Cdk2) activity at the G1 to S boundary has a role in the resistance of Chronic Myeloid Leukemia (CML) haematopoietic progenitors to the tyrosine kinase inhibitor STI571 (Imatinib) 138
Prognostic factors in primary cutaneous B-cell lymphoma: the Italian Study Group for Cutaneous Lymphomas. 138
P53 oncosuppressor influences selection of genomic imbalances in response to ionizing radiations in human osteosarcoma cell line SAOS-2 137
A new class of dual SRC/ABL kinase inhibitors for the treatment of imatinib-resistant chronic myeloid leukemias 137
RAD001 (everolimus) prevents mTOR and Akt late re-activation in response to imatinib in chronic myeloid leukemia 135
Post-translational modifications of FOXO3a transcription factor associated with the constitutive tyrosine kinase activity of p210 BCR-ABL protein. Implications for new targeted therapies 130
P210 BCR-ABL tyrosine kinase prevents apoptotic cell death through multiple pathways converging at mitochondrial membranes 128
Idetification of the first non-peptidic small molecule inhibitor of the c-Abl/14-3-3 protein-protein interactions able to drive sensitive and Imatinib-resistant leukemia cells to apoptosis. 118
We are very happy and proud of this monographic issue of the Giornale Italiano di Dermatologia e Venereologia. Introduction. 100
La tirosin-cinasi del prodotto p210 di bcr-abl sopprime l'apoptosi mitocondrio dipendente 92
NEW STRATEGIES IN THE TREATMENT OF CHRONIC MYELOID LEUKEMIA. COMBINED USE OF SRC AND TYROSINE KINASE INHIBITORS CIRCUMVENTS THE DEVELOPMENT OF DRUG-RESISTANCE 76
The Haemolymphopathology Italian Group (H.I.G.): an essential resource for the new technical and organization problems troubling modern haemolymphopathology diagnostics 71
Computational techniques are valuable tools for the discovery of protein-protein interaction inhibitors: the 14-3-3 sigma case. 2
Totale 9.115
Salva come PNG Salva come JPEG
Categoria #
all - tutte 23.561
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 23.561
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021290 0 0 0 0 0 0 0 0 0 0 0 290
2021/20221.118 190 28 86 81 87 58 27 58 31 72 210 190
2022/20231.189 133 205 71 145 82 107 25 51 189 32 85 64
2023/2024304 18 49 16 49 19 79 22 14 8 13 8 9
2024/20251.016 19 149 96 73 181 61 53 62 10 139 15 158
2025/20262.556 217 214 193 164 372 168 214 123 534 211 71 75
Totale 9.115